Bit.bio
Health
· Headquartered in United Kingdom 🇬🇧
Track Bit.bio
— get Health deals in free daily digest
Overview
Cambridge-based biotech firm bit.bio has raised $50 million in funding, led by M&G Investments. The funding will accelerate product development, enhance accessibility, and expand into the toxicology market. Bit.bio's technology provides reliable human cells for research, reducing reliance on animal testing and improving pre-clinical research accuracy. CEO Przemek Obloj emphasized the importance of this investment in driving innovation in drug development.
Products
Loading...
Synthesising company profile
Reading press coverage to extract founders, customers, traction signals and competitive positioning…
Recent Announcements
Investors: M&G Investments
Cambridge-based biotech firm bit.bio has raised $50 million in funding, led by M&G Investments. The funding will accelerate product development, enhance accessibility, and expand into the toxicology market. Bit.bio's technology provides reliable human cells for research, reducing reliance on animal testing and improving pre-clinical research accuracy. CEO Przemek Obloj emphasized the importance of this investment in driving innovation in drug development.
More Health Deals
Market Map
View thousands of companies by category in our market map:
